



PROVIDER NOTICE

Provider Relations Department: 888-895-4998 (Option 4)

New Laboratory Developed Test Codes for USFHP

Effective Date: March 25, 2025

Health Plans Affected: US Family Health Plan (USFHP)

Type of Change: Prior Authorization Status, Covered Benefit

Explanation of Change:

Per the TRICARE® Operations Manual (TOM), selected new codes on the Laboratory Developed Test (LDT) Codes List (see below) are now covered and require prior authorization beginning March 25, 2025.

- **0312U** - Autoimmune diseases (e.g. systemic lupus erythematosus [SLE]) analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent
- **0334U** - Oncology (solid organ) targeted genomic sequence analysis formalin-fixed paraffin embedded (FFPE) tumor tissue DNA analysis 84 or more genes interrogation
- **0422U** - Oncology (pan-solid tumor) analysis of DNA biomarker response to anti-cancer therapy using cell-free circulating DNA biomarker comparison to a previous baseline pre-treatment
- **81479** - Unlisted molecular pathology procedure
- **81599** - Unlisted multianalyte assay with algorithmic analysis

Prior authorization process for USFHP:

Submit prior authorization requests to the Johns Hopkins Health Plans Utilization Management (UM) department using these dedicated fax numbers: 410-424-2602 or 410-424-2603.

TRICARE is a registered trademark of the Department of Defense, Defense Health Agency. All rights reserved.